A method for estimating hepatitis B virus incidence rates in volunteer blood donors. National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study.
about
Which is safer source plasma for manufacturing in China: apheresis plasma or recovered plasma?Comparison of epidemiological methods for estimation of hepatitis B incidence and residual risk for blood donors in southern BrazilOccult hepatitis B virus infection and blood transfusionReducing the risk of hepatitis B virus transfusion-transmitted infectionIncidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000.The National Heart, Lung, and Blood Institute retrovirus epidemiology donor studies (Retrovirus Epidemiology Donor Study and Retrovirus Epidemiology Donor Study-II): twenty years of research to advance blood product safety and availability.New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods.Hepatitis B virus blood screening: unfinished agendas.Two cases of transfusion-transmitted hepatitis B virus (HBV) infection in a low-endemic country before implementation of HBV nucleic acid testing.Incidence and Residual Risk of HIV, HBV and HCV Infections Among Blood Donors in Tehran.Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus.Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT.Estimated risk of transfusion-transmitted viral infections in Spain.The yield of universal antibody to hepatitis B core antigen donor screening in the Netherlands, a hepatitis B virus low-endemic country.Current incidence and residual risk of HIV, HBV and HCV at Canadian Blood Services.Trends in prevalence, incidence, and residual risk of major transfusion-transmissible viral infections in United Arab Emirates blood donors: impact of individual-donation nucleic acid testing, 2004 through 2009.A prospective study of the risk of transfusion-acquired viral infections.Results of viral marker screening of unpaid blood donations and probability of window period donations in 1997. EPFA Working Group on Quality Assurance.Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004.HIV seroconverting donors delay their return: screening test implications.The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations.Hepatitis B and residual risk of infection in English and Welsh blood donors, 1996 through 2008.Enhanced detection of hepatitis B virus in Hong Kong blood donors after introduction of a more sensitive transcription-mediated amplification assay.Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms.Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk.Residual risk of transfusion-transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy.Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services.Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands.Residual risk of transfusion-transmitted HCV and HIV infections by antibody-screened blood in Italy.International application of the incidence rate/window period model.Prevalence and estimated incidence of blood-borne viral pathogen infection in organ and tissue donors from northern Alberta.Trends in residual risk of transfusion-transmitted viral infections in France between 1992 and 2000.Infectious disease markers in young blood donors. Retrovirus Epidemiology Donor Study.Value of retaining HBsAg donor screening where HBV NAT and anti-HBc donor screening applyTransfusion-transmitted HBV infection in an endemic area: the necessity of more sensitive screening for HBV carriersPrevalence, incidence and residual risk of transfusion-transmitted hepatitis C virus and human immunodeficiency virus after the implementation of nucleic acid testing in Italy: a 7-year (2009-2015) surveyResidual Risk of Hepatitis-B-Infected Blood Donations: Estimation Methods and Perspectives
P2860
Q33432155-036EFD1B-22DB-4BF7-B731-F270F366EC6FQ34147896-97B30C8D-C026-434F-9E45-527892A398DAQ35237335-539FC68B-F2FB-4A93-BE48-B5AD1D3E0E8CQ35683881-18A3A481-D641-47FB-8AF8-346F4D055831Q36078723-4A13696A-8C11-42D2-9F53-448986055D04Q36252455-AA4DB613-C19A-4508-90D1-1D3333F09354Q36466447-0E2B0643-8313-4323-8135-B50FC2F69EB3Q36498410-9372B4FA-07D8-48CC-9834-4D5E3B8B1F64Q38403039-203AFF59-432B-4F47-85A2-6C6991E4CF0BQ40077221-F0DBD5B5-A1AD-48CE-BD0C-5277124242D3Q40383406-B1D47FDB-99DD-4572-BFE9-23034328A4F8Q40622701-2ECE339D-7E0A-4A79-BF53-77F684C31B1CQ40626774-E0A42288-6EF2-4D3F-8CCE-3BD3BC706E7AQ41606333-7784C73A-329E-460B-BE51-1DCF0AD0A126Q42977201-04527DE0-FD50-44B6-9F17-DFB52E757D3CQ42981169-09265782-05F1-4612-A5CE-4BF0B5A267D9Q42990689-F952B539-DFA6-429B-8551-A16F5CA7D250Q42998860-9C0092D0-1824-4124-97BB-1224AABC1D53Q43036225-88BD33F4-D78D-41B4-BC8C-9DA39B2285C1Q43038339-8BF0A1C1-E06A-4FFE-804C-C0956C1E0F4BQ43048511-9273C263-31E3-43BC-B36B-B22BAB476ACCQ43851125-57D2F10E-AAA0-4CF7-88AB-D481D891B294Q44164538-3B8FA254-764B-44BA-BFD3-5C79018583E3Q44540335-49D0CB63-A379-43F1-B0EF-A4DC0621D8A3Q45362712-929CFF52-7239-473A-8F77-DF16E44DFC4FQ45423755-25DE53F1-3350-4392-B55A-31EB191622B2Q48081521-0A1E9BC6-0328-42DC-A316-9E6EC914E7F5Q51940682-8122EE41-04FF-45A1-9C69-4606E6A7C83EQ52030298-105177D4-4080-4B68-A2E6-A09DE933C3DBQ53307878-41E4176C-8635-4FBB-9801-BF2D13DBDE2FQ55239416-CCFFB23B-38AA-4AB9-8FC0-11DED482F137Q55239686-16D93882-159C-41FF-B672-7CCC1F43738FQ55239938-EB8E7212-C84A-4A6C-B2C7-6D7F7F4528F7Q57176158-D5FA38BA-025D-4735-A49B-00FD6EB054F8Q57205463-7E36A8D4-5DBF-4586-96D5-A7553987A4F9Q58776091-021C4D78-5109-4287-97DA-BB623A865787Q58999805-A6EA1DD7-0EE9-4D6A-BCBB-2EE7A33F3395
P2860
A method for estimating hepatitis B virus incidence rates in volunteer blood donors. National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
A method for estimating hepati ...... irus Epidemiology Donor Study.
@en
A method for estimating hepati ...... irus Epidemiology Donor Study.
@nl
type
label
A method for estimating hepati ...... irus Epidemiology Donor Study.
@en
A method for estimating hepati ...... irus Epidemiology Donor Study.
@nl
prefLabel
A method for estimating hepati ...... irus Epidemiology Donor Study.
@en
A method for estimating hepati ...... irus Epidemiology Donor Study.
@nl
P2093
P1433
P1476
A method for estimating hepati ...... irus Epidemiology Donor Study.
@en
P2093
Gilcher RO
Kleinman SH
Korelitz JJ
Schreiber GB
Williams AE
P304
P356
10.1046/J.1537-2995.1997.37697335159.X
P577
1997-06-01T00:00:00Z